NTRA NTRA

Name: NTRA Crucible Score
Creator: Kaladin Capital Intelligence

UnknownUnknownN/A📅 Scored April 5, 2026

Price at analysis: $207.98

Crucible Score

47.6

C-

Quality × Value Composite

KQI — Quality

56.0

Fundamental Quality Index

KVI — Value

37.4

D-

Valuation Attractiveness Index

Crucible Verdict — NTRA

Netra Inc. (NTRA) presents a classic growth-quality mismatch with strong Growth Profile (75) and Moat Durability (70) scores undermined by weak Financial Quality (38) and poor Diversification & Resilience (20). The 81% earnings beat rate demonstrates execution capability, but insider selling raises red flags. NTRA trades at a 10% discount to fair value, making it appealing only for investors comfortable with concentrated risk exposure.

— Kal, Kaladin Capital Intelligence

◆ KQI Quality Dimensions

Financial Quality⚠

37.5

Growth Profile⚠

75.4

Moat Durability

70.0

Management Effectiveness⚠

55.2

Diversification & Resilience⚠

20.0

Market Position

53.0

Weakest dimension: Diversification & Resilience (20.0)

◆ KVI Value Dimensions

DCF Margin of Safety

53.6

FCF Yield & Cash Returns

8.2

Relative Valuation

45.9

Growth-Adjusted Value

35.0

Historical Valuation

50.0

Macro Context

5.0

◆ DCF Valuation Scenarios

Bear Case

$131.52

Base Case

$228.45

Bull Case

$372.18

Price at Analysis

$207.98

Scenario	Fair Value	Rev CAGR (5yr)	Terminal Margin	WACC
🔴 Bear	$131.52	14.0%	18.0%	13.4%
🟢 Base	$228.45	18.0%	22.0%	12.4%
🟢 Bull	$372.18	22.0%	27.0%	11.4%

Key Assumptions: NTRA has demonstrated strong revenue growth (~36% CAGR over 5 years from $625M to $2306M) with rapidly improving margins moving from -75% operating margin to -13%, and recently turning FCF positive at $109M. WACC calculated using CAPM with 4.31% risk-free rate, 1.68 beta, and 5.4% ERP yielding ~13.4% base cost of equity, with scenarios spanning +/-1% around base. Key judgment: the company is on a path to profitability with operating margins expected to reach 18-27% at terminal state given the high-margin diagnostics business model, but still below mature diagnostics peers given ongoing R&D intensity.

◆ Financial Snapshot

Profitability

Gross Margin64.8%

Operating Margin-13.4%

Net Margin-9.0%

ROIC-12.0%

ROE-135.1%

Balance Sheet

Balance SheetCR: 3.39

Cash Conversion

Capital IntensityCapex/Rev: 4.6%

Altman Z-Score21.77 (Safe)

Piotroski F-Score4/9 (Mixed)

Growth

Revenue CAGR38.6% CAGR

Earnings CAGRInsufficient data

Growth ConsistencyCV: 0.58

Segment Breadth1/2 growing (50%)

Quarterly TrendRev↑, Margin↑, Exp↓

Earnings CredibilityTends to Beat

◆ Analyst Consensus & Leadership

Leadership & Governance

CEO Ownership5.6%

Insider ActivitySelling

Earnings Beat Rate81% (19/22)

◆ Related Companies in Our Universe

Other Unknown companies scored by the Crucible:

ADBE81.8A-NICE80.7A-DECK79.9A-INTU79.9A-EXEL78.3A-MTCH78.2A-TTD78.0B+

Methodology All Scores Crucible Briefs Performance @KaladinCI

Analysis conducted April 5, 2026 based on most recent SEC filings. Updated quarterly, after new SEC filings.

Point-in-time fundamental analysis. Not investment advice. Scores reflect company quality and valuation at time of analysis and may not reflect current market conditions.